# United States SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

# Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 17, 2008

# ICU Medical, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation) 0-19974 (Commission File Number) 33-0022692 (IRS Employer Identification No.)

**951 Calle Amanecer, San Clemente, California** (Address of principal executive offices) 92673 (Zip Code)

Registrant's telephone number, including area code: (949) 366-2183

NA (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 2.02. Results of Operations and Financial Condition.

ICU Medical, Inc. announced its earnings for the first quarter 2008.

## Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press release, dated April 17, 2008 announcing ICU Medical, Inc.'s first quarter 2008 earnings.

# SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICU Medical, Inc.

(Registrant)

(Date)

Scott E. Lamb Secretary, Treasurer and Chief Financial Officer

### ICU Medical, Inc. Reports First Quarter 2008 Results

#### Company Reaffirms Full-Year 2008 Outlook of \$200 Million in Revenue and Diluted Earnings of \$1.50 Per Share

SAN CLEMENTE, Calif., April 17, 2008 (PRIME NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leading low cost manufacturer of safe medical connectors, custom medical products and critical care devices, today announced results for the first quarter ended March 31, 2008.

First quarter of 2008 revenue was \$44.7 million, compared to \$48.8 million in the same period last year. Net income for the first quarter of 2008 was \$2.9 million, or \$0.20 per diluted share, as compared to net income of \$4.5 million, or \$0.29 per diluted share, for the first quarter of 2007. The first quarter of 2007 results exclude the after tax income benefit from a legal settlement of \$5.3 million or 34 cents per share.

Scott Lamb, ICU Medical's Chief Financial Officer said, "We are pleased with our first quarter results which were in line with our expectations. The strong performance of our new oncology products line and existing CLAVE and custom CLAVE products were partially offset by a decline in critical care products distributed by Hospira. During the first quarter, Hospira deployed a dedicated team to sell our critical care products and we are optimistic that this team combined with new products will enable us to eventually experience better results from this product line.

"In the latter half of the first quarter 2008, we initiated a full launch of our oncology portfolio of products. This line generated sales of \$1.3 million during the first quarter 2008 and we are on track to increase our oncology sales tenfold in 2008 compared to 2007."

Mr. Lamb continued, "During the last 10 days of December and early January, we reduced our plant operating hours in order to perform planned preventative maintenance and this affected our gross margins by three and a half percentage points. Excluding this maintenance, we would have achieved gross margins of 43% compared to 39% for the comparable period last year."

Operating cash flow was \$4.7 million for the first quarter of 2008. As of March 31, 2008, cash and investments totaled \$99.1 million and working capital was \$136.5 million.

For the full fiscal year of 2008, management reaffirmed its outlook of approximately \$200 million in revenue and diluted earnings of approximately \$1.50 per share.

The Company will be conducting a conference call concerning its first quarter ended March 31, 2008 results at 4:30 p.m. EDT (1:30 p.m. PDT) on Thursday, April 17, 2008. The call can be accessed at 800-561-2718, passcode 47135968 or by replay at 888-286-8010, passcode 75011305. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay. Certain information provided as part of that call will be provided on the Company's website at http://www.icumed.com within 48 hours of the call.

The foregoing statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results. Future results are subject to risks and uncertainties, including the risk factors described in the Company's filings with the Securities and Exchange Commission, which include those in the Form 10-K for the year ended December 31, 2007. Actual results in the future may differ materially from Management's current expectations.

#### ICU Medical, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Amounts in thousands, except share and per share data)

ASSETS

	3/31/08	12/31/07
	(unaudited)	(1)
CURRENT ASSETS:		
Cash and cash equivalents	\$ 37 <b>,</b> 595	\$ 7 <b>,</b> 873
Marketable securities	61,540	87,770
Cash, cash equivalents and marketable		
securities investments	99,135	95,643
Accounts receivable, net of allowance for doubtful accounts of \$583 and \$655 as of March 31, 2008 and December 31, 2007,		
respectively	26,354	26,115
Inventories	21,275	19,504
Prepaid income taxes	,	2,740
Prepaid expenses and other current assets	•	4,746
Deferred income taxes - current portion	4,181	
bereffed income caneb callence porcion		
Total current assets	156,729	153,257
PROPERTY AND EQUIPMENT, net	73,677	72,708

INTANGIBLE ASSETS, net DEFERRED INCOME TAXES - non-current INCOME TAXES RECEIVABLE - non-current OTHER ASSETS	11,600 2,689 1,848 465	11,884 2,432 1,848 465
	\$247 <b>,</b> 008	\$242,594
LIABILITIES AND STOCKHOLDERS' H	EQUITY	
CURRENT LIABILITIES:		
Accounts payable	\$ 7,741	\$ 8,439
Accrued liabilities	12,515	13,036
Total current liabilities	20,256	21,475
DEFERRED INCOME TAXES - non-current portion	4,325	4,325
INCOME TAXES PAYABLE - non-current portion	2,890	2,890
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY: Convertible preferred stock, \$1.00 par value - Authorized - 500,000 shares,		
issued and outstanding - none Common stock, \$0.10 par value - Authorized - 80,000,000 shares, issued 14,746,951 shares		
at March 31, 2008 and December 31, 2007	1,475	1,475
Additional paid-in capital	70,846	74,805
Treasury stock, at cost - 890,673 and 1,057,501 shares at March 31, 2008 and		
December 31, 2007, respectively Unrealized holding loss	(34,183) (635)	(40,776)
Retained earnings	179,902	177,004
Accumulated other comprehensive income	2,132	1,396
Total stockholders' equity	219,537	213,904
	\$247,008	\$242,594 =======

 December 31, 2007 balances were derived from audited consolidated financial statements.

#### ICU Medical, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Amounts in thousands, except share and per share data) (unaudited)

	Quarter ended March 31,		
		2008	 2007
REVENUES: Net sales Other	\$ 	43,671 983	47,663 1,170
TOTAL REVENUE		44,654	48,833
COST OF GOODS SOLD		26,883	29,617
Gross profit		17,771	 19,216
OPERATING EXPENSES: Selling, general and administrative Research and development		13,108 2,019	11,999 1,851
Total operating expenses, net		15,127	 13,850
Income from operations		2,644	5,366
OTHER INCOME		1,556	9,399

Income before income taxes and minority interest	4,200	14,765
PROVISION FOR INCOME TAXES MINORITY INTEREST	(1,302)	(5,020) 70
NET INCOME	\$    2,898	\$
NET INCOME PER SHARE Basic Diluted	\$ 0.21 \$ 0.20	\$ 0.67 \$ 0.63
WEIGHTED AVERAGE NUMBER OF SHARES Basic Diluted	13,751,622 14,375,751	14,581,699 15,614,711

#### ICU Medical, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Amounts in thousands) (unaudited)

	Quarter ended	
	2008	2007
CASH FLOWS FROM OPERATING ACTIVITIES: Net income Adjustments to reconcile net income to net cash provided by operating activities:		\$ 9,815
Depreciation and amortization Provision for doubtful accounts Minority interest Stock compensation Cash provided (used) by changes in operati:	3,410 (38)  416	2,566 57 (70) 181
assets and liabilities Accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued liabilities Prepaid and deferred income taxes	172 (1,646) 566 (699) (568) 152	(306) 151 (560) (550) 327 4,769
Net cash provided by operating activities	4,663	16,380
CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment Proceeds from finance loan repayments Purchases of marketable securities Proceeds from sale of marketable securities	(3,592) 24 (9,027) 34,622	(7,064) 23 (17,790) 11,729
Net cash provided (used) by investing activities	22,027	(13,102)
CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of stock options Proceeds from employee stock purchase plan Tax benefits from exercise of stock options Purchase of treasury stock	1,071 744 954	602 742 140 (8,613)
Net cash provided (used) by financing activities	2,769	(7,129)
Effect of exchange rate changes on cash	263	4
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	29,722	(3,847)
CASH AND CASH EQUIVALENTS, beginning of period	7,873	13,153

\$ 37 <b>,</b> 595	\$ 9,306

CONTACT: ICU Medical, Inc. Scott E. Lamb, Chief Financial Officer (949) 366-2183

> Integrated Corporate Relations John F. Mills, Managing Director (310) 954-1100